Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience

Gerardo Calderon,Daniel Gonzalez-Izundegui,Kuangda L. Shan,Oscar A. Garcia-Valencia,Lizeth Cifuentes,Alejandro Campos,Maria L. Collazo-Clavell,Meera Shah,Daniel L. Hurley,Haitham S. Abu Lebdeh,Mayank Sharma,Kristine Schmitz,Matthew M. Clark,Karen Grothe,Manpreet S. Mundi,Michael Camilleri,Barham K. Abu Dayyeh,Maria D. Hurtado Andrade,Mohamad A. Mokadem,Andres Acosta
DOI: https://doi.org/10.1038/s41366-021-01019-6
2021-11-22
International Journal of Obesity
Abstract:Background and aimsRandomized clinical trials have proven the efficacy and safety of Food and Drug Administration (FDA) approved anti-obesity medications (AOMs) for long-term use. It is unclear whether these outcomes can be replicated in real-world clinical practice where clinical complexities arise. The aim of this study was to evaluate the effectiveness and side effects of these medications in real-world multidisciplinary clinical practice settings.MethodsWe reviewed the electronic medical records (EMR) of patients with obesity who were prescribed an FDA-approved AOM for long-term use in academic and community multidisciplinary weight loss programs between January 2016 and January 2020.InterventionWe assessed percentage total body weight loss (%TBWL), metabolic outcomes, and side effect profile up to 24 months after AOM initiation.ResultsThe full cohort consisted of 304 patients (76% women, 95.2% White, median age of 50 years old [IQR, 39–58]). The median follow-up time was 9.1 months [IQR, 4.2–14.1] with a median number of 3 visits [IQR, 2–4]. The most prescribed medication was phentermine/topiramate extended-release (ER) (51%), followed by liraglutide (26.3%), bupropion/naltrexone sustained-release (SR) (16.5%), and lorcaserin (6.2%). %TBWL was 5.0%, 6.8%, 9.3%, 10.3%, and 10.5% at 3, 6, 12, 18, and 24 months. 60.2% of the entire cohort achieved at least 5% TBWL. Overall, phentermine/topiramate-ER had the most robust weight loss response during follow-up, with the highest %TBWL at 12 months of 12.0%. Adverse events were reported in 22.4% of patients. Only 9% of patients discontinued the medication due to side effects.ConclusionsAOMs resulted in significant long-term weight loss, that was comparable to outcomes previously reported in clinical trials.
endocrinology & metabolism,nutrition & dietetics
What problem does this paper attempt to address?